Bio Green Med Solution, Inc. (BGMS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) on September 12, 2025. The registrant is incorporated in Delaware and maintains its principal executive offices in Kuala Lumpur, Malaysia. The report addresses a specific listing deficiency regarding the company's Preferred Stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Deficiency
On September 11, 2025, the company received notice from Nasdaq that its 6% Convertible Exchangeable Preferred Stock (trading symbol "BGMSP") failed to meet the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $1 million under Nasdaq Listing Rule 5460(a)(2). This non-compliance persisted for the prior 30 consecutive business days. The Common Stock (trading symbol "BGMS") is not affected by this deficiency.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted 180 calendar days, until March 10, 2026, to regain compliance with the MVPHS requirement.
- Trading Status: The Preferred Stock will continue to trade on the Nasdaq Capital Market during this compliance period.
- Regaining Compliance: Compliance will be achieved if the MVPHS equals or exceeds $1 million for a minimum of 10 consecutive business days before the deadline.
- Delisting Risk: If compliance is not met by March 10, 2026, the Preferred Stock will be delisted. The company retains the right to appeal any delisting determination to a Nasdaq hearings panel.
- Management Action: Management intends to actively monitor the MVPHS and evaluate various options to restore compliance if the stock price does not naturally recover.
Key Facts for Investor Verification
- Verify the current market price and public float of the Preferred Stock (BGMSP) to assess the likelihood of meeting the $1 million MVPHS threshold.
- Confirm the specific terms of the 6% Convertible Exchangeable Preferred Stock to understand conversion mechanics that might impact share count or value.
- Monitor subsequent filings for any announcements regarding capital raises, reverse stock splits, or other corporate actions intended to restore listing compliance.
- Review the company's most recent 10-K or 10-Q filings for underlying financial health, as this 8-K does not contain operational financial data.